Drugs / US-ATG-F
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01295710 Comparator | Oct 2011 → Oct 2015 | acute myeloid leukemia, adult acute lymphoblastic leukemia, graft versus host disease, myelodysplastic syndrome | Neovii Biotech | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | US-ATG-F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01295710 ↗ |
| Modality | Protein / enzyme biologic | “anti-thymocyte globulins (ATGs), a set of polyclonal antibodies directed against a variety of immune cell epitopes” PMID 37341189 ↗ Jun 2023 |
| Route | Intravenous | “IV infusion over 6-16 hours 3 days prior to transplantation” NCT01295710 ↗ |